Multi-target therapeutics and new drug discovery

Yaoxue Xuebao

Volumn 44, Issue 3, 2009, Pages 226-230

  Xu, Yan ^a   Li, Xue Jun ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Multi target; Multicomponent drug; Multidrug combination; Synergistic effect

Indexed keywords

DRUG SCREENING; DRUG TARGETING; MULTIDRUG RESISTANCE; REVIEW;

DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; DRUG INTERACTIONS; DRUG SYNERGISM; DRUG THERAPY; DRUGS, CHINESE HERBAL; HUMANS;

EID: 67249123401     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? [J]. Nat Rev Drug Discov, 2004, 3: 711-716.
2. Bolognesi ML, Cavalli A, Meichiorre C. Memoquin: A multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease [J]. Neurotherapeutics, 2009, 6: 152-162.
3. Pollio G Roncarati R, Seredenina T, et al. A reporter assay for target validation in primary neuronal cultures [J]. J Neurosci Meth, 2008, 172: 34-37.
4. Schrattenholz A, Soskic V. What does systems biology mean for drug development? [J]. Cur Med Chem, 2008, 15: 1520-1528.
5. Zimmermann GR, Lehar J, Keith CT. Multi-target therapeutics: When the whole is greater than the sum of the parts [J]. Drug Discov Today, 2007, 12: 34-42.
6. Gupta GP, Nguyen DX, Chiang AC, et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis [J]. Nature, 2007, 446: 765-770.
7. Zent CS. The role of alemtuzumab in the treatment of chronic lymphocytic leukemia [J]. Leuk Lymphoma, 2008, 49: 175-176.
8. Hopkins AL. Network pharmacology: The next paradigm in drug discovery [J]. Nat Chem Biol, 2008, 4: 682-690.
9. Petrelli A, Giordano S. From single-to multi-target drugs in cancer therapy: When a specificity becomes an advantage [J]. Curr Med Chem, 2008, 15: 422-432.
10. Mayer T, Jagla B, Wyler MR, et al. Cell based assays using primary endotheial cells to study multiple steps in inflammation [J]. Method Enzymul, 2006, 414: 266-283.
11. Crawford AD, Esguerra CV, de Witte PA. Fishing for drugs from nature: Zebrafish as a technology platform for natural product discovery [J]. Planta Mcd, 2008, 74: 624-632.
12. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2 - deficient tumours with inhibitors of poly(ADP-ribose) polymerase [J]. Nature, 2005, 434: 913-917.
13. Borisy AA, Elliott PJ, Hurst NW, et al. Systematic discovery of multicomponent therapeutics [J]. PNAS, 2003, 100: 7977-7982.
14. Morphy R, Kay C, Rankovic Z. From magic bullets to designed multiple ligands [J]. Drug Discov Today, 2004, 9: 641-651.
15. Cashman JR, Voelker T, Johnson R, et al. Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression [J]. Bioorg Med Chem, 2009, 17: 337-343.
16. Murugesan N, Tellew JE, Gu ZX, et al. Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists [J]. J Med Chem, 2002, 45: 3829-3835.
17. Abdel-Malak M, Gallati C, Mousa SA. The rise of second-generation non-nucleoside reverse transcriptase inhibitors: Etravirine, rilpivirine, UK-453061 and RDEA-806 [J]. Drug Future, 2008, 33: 691-699.
18. Chen X, Zhou H, Liu YB, et al. Database of traditional Chinese medicine and its application to studies of mechanism and to prescription validation [J]. Br I Pharmacol, 2006, 149: 1092-1103.
19. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins [J]. Cancer Lett, 2008, 269: 199-225.
20. Nahta R, Yuan LXH, Du Y, et al. Lapatinib induces apoptosis in trastuzumab - resistant breast cancer cells: Effects on insulin-like growth factor I signaling [J]. Mol Cancer Ther, 2007, 6: 667-674.
21. Smlley D, Umpierrez U Metformin/rosiglitazone combination pill (Avandamet) for the treatment of patients with Type 2 diabetes [J]. Expert Opin Pharmacother, 2007, 8: 1353-1364.
22. Giaquinto C, Morelli E, Fregonese F, et al. Current and future antiretroviral treatment options in paediatric HIV infection [J]. Clin Drug Invest, 2008, 28: 375-397.
23. Zhang X, Crespo A, Fernandez A. Turning promiscuous kinase inhibitors into safer drugs [J]. Trends Biotechnol, 2008, 26: 295-301.